BIOMAT Database Logo BIOMAT Database Logo

[New antiarrhythmic agents in atrial fibrillation]. 2007

Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
Departamento de Farmacología, Instituto Nacional de Cardiología lgnacio Chávez, Tialpan 14080, México DF.

The convenience to count with a safe and effective pharmacological wealth for atrial fibrillation treatment had conduced, in a way, to a deep depuration of the vast array of antiarrhythmic drugs, keeping only a very restricted number of compounds with a widely proved anti-atrial activity. On the other hand, it had lead to the discovery of the pathophysiological concepts that point to novel therapeutic targets. Within these objectives is that new antiarrhythmic drugs with preferential, even selective, activity on myocardial atrium ion channels had been developed. Among these new antiarrhythmics, dofetilide, and AVE0118, are taken into account. In addition, new possibilities are opened based on the knowledge of the cardioprotective-antiarrhythmic qualities of the opioidergic system.

UI MeSH Term Description Entries
D007473 Ion Channels Gated, ion-selective glycoproteins that traverse membranes. The stimulus for ION CHANNEL GATING can be due to a variety of stimuli such as LIGANDS, a TRANSMEMBRANE POTENTIAL DIFFERENCE, mechanical deformation or through INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS. Membrane Channels,Ion Channel,Ionic Channel,Ionic Channels,Membrane Channel,Channel, Ion,Channel, Ionic,Channel, Membrane,Channels, Ion,Channels, Ionic,Channels, Membrane
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D011957 Receptors, Opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. Endorphin Receptors,Enkephalin Receptors,Narcotic Receptors,Opioid Receptors,Receptors, Endorphin,Receptors, Enkephalin,Receptors, Narcotic,Receptors, Opiate,Endorphin Receptor,Enkephalin Receptor,Normorphine Receptors,Opiate Receptor,Opiate Receptors,Opioid Receptor,Receptors, Normorphine,Receptors, beta-Endorphin,beta-Endorphin Receptor,Receptor, Endorphin,Receptor, Enkephalin,Receptor, Opiate,Receptor, Opioid,Receptor, beta-Endorphin,Receptors, beta Endorphin,beta Endorphin Receptor,beta-Endorphin Receptors
D004594 Electrophysiology The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
D006325 Heart Atria The chambers of the heart, to which the BLOOD returns from the circulation. Heart Atrium,Left Atrium,Right Atrium,Atria, Heart,Atrium, Heart,Atrium, Left,Atrium, Right
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001281 Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation. Auricular Fibrillation,Familial Atrial Fibrillation,Paroxysmal Atrial Fibrillation,Persistent Atrial Fibrillation,Atrial Fibrillation, Familial,Atrial Fibrillation, Paroxysmal,Atrial Fibrillation, Persistent,Atrial Fibrillations,Atrial Fibrillations, Familial,Atrial Fibrillations, Paroxysmal,Atrial Fibrillations, Persistent,Auricular Fibrillations,Familial Atrial Fibrillations,Fibrillation, Atrial,Fibrillation, Auricular,Fibrillation, Familial Atrial,Fibrillation, Paroxysmal Atrial,Fibrillation, Persistent Atrial,Fibrillations, Atrial,Fibrillations, Auricular,Fibrillations, Familial Atrial,Fibrillations, Paroxysmal Atrial,Fibrillations, Persistent Atrial,Paroxysmal Atrial Fibrillations,Persistent Atrial Fibrillations
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl

Related Publications

Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
New antiarrhythmic agents for atrial fibrillation.
January 2001, Current opinion in investigational drugs (London, England : 2000),
Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
New antiarrhythmic agents for atrial fibrillation and atrial flutter.
May 2005, Expert opinion on emerging drugs,
Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
Antiarrhythmic drug therapy of atrial fibrillation: focus on new agents.
June 2003, Journal of cardiovascular pharmacology and therapeutics,
Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation.
May 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
New antiarrhythmic targets in atrial fibrillation.
January 2015, Future cardiology,
Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation.
November 2007, Journal of cardiovascular electrophysiology,
Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
New antiarrhythmic treatment of atrial fibrillation.
July 2007, Expert review of cardiovascular therapy,
Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
[New antiarrhythmic drugs for atrial fibrillation].
December 2009, Annales de cardiologie et d'angeiologie,
Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
November 1999, The American journal of cardiology,
Gustavo Pastelín Hernández, and Pastor Luna Ortíz, and Fermín Alejandro Tenorio López, and Leonardo del Valle Mondragón
[Atrial fibrillation : new anticoagulants and antiarrhythmic drugs].
March 2012, Herz,
Copied contents to your clipboard!